US equities |
SPCX $167.61 ▲+5.44% NVDA $237.18 ▲+1.38% MU $1,065.50 ▼-0.87% TSLA $377.95 ▲+1.99% MSFT $525.29 ▲+1.50% SNDK $1,708.25 ▼-0.68% INTC $116.99 ▼-1.96% META $743.93 ▲+2.18%
FinancialContent

Olema Pharmaceuticals, Inc. - Common Stock (NQ:OLMA)

8.110 -0.120 (-1.46%)
Delayed Quote Updated: 1:04 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Olema Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Why Bain Capital Is Selling Shares of This Biotech Stock Now ↗
Bain Capital sold $20 million worth of Pharvaris stock during the third quarter. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Top movers in Tuesday's session ↗
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Pharma Bro Martin Shkreli Shorts Olema Pharmaceuticals Stock ↗
"Pharma Bro' and notorious bear Martin Shkreli is shorting Olema Pharmaceuticals stock. 
Via Benzinga
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
OLMA Stock Doubles After Roche Cancer Drug Trial Yields Positive Results ↗
Roche was evaluating Giredestrant as an adjuvant endocrine treatment for people with certain types of early-stage breast cancer. 
Via Stocktwits
News headline image
Amer Sports Posts Upbeat Q3 Earnings, Joins Diginex, James Hardie Industries And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Cancer Focused Olema Pharmaceuticals Stock Soars 150% - Here's Why ↗
Roche posts positive phase 3 results for giredestrant in early breast cancer, showing improved disease-free survival and a favorable safety profile. 
Via Benzinga
News headline image
Dow Falls Over 300 Points; Home Depot Posts Downbeat Earnings ↗
 
Via Benzinga
Topics Stocks
News headline image
Why Roche's Positive Test Results Sent Olema Pharma Skyrocketing 200% ↗
The companies are both working on oral selective estrogen receptor degraders, which break down the estrogen cancer cells need to grow. 
Via Investor's Business Daily
Topics Government
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Gorilla Technology Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Olema Oncology Reports Third Quarter 2025 Financial and Operating Results
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology to Participate in Upcoming Investor Conferences
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025
From Olema Oncology
Via GlobeNewswire
News headline image
Top 3 Health Care Stocks You'll Regret Missing In October ↗
 
Via Benzinga
News headline image
These stocks are moving in today's pre-market session ↗
As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
News headline image
Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Delcath Systems Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology to Participate in Upcoming Investor Conferences
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology Reports Second Quarter 2025 Financial and Operating Results
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >